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          ABSTRACT 
 
In many cystic fibrosis (CF) centers, consultation from gastroenterologist, are not 
routinely taken. Yet the original name ‘cystic fibrosis of the pancreas’ illustrates the 
importance of the digestive system in this disease. Nutritional status, occurrence of CF 
related diabetes, liver involvement, morbidity and mortality are largely associated with 
pancreatic function. Treatment depends on treating associated conditions as well. 
Knowledge of exocrine pancreatic function, sufficiency or insufficiency, is therefore 
paramount from diagnosis on. At present the best test for this purpose is determination 
of fecal elastase-1, which should therefore be used in clinical practice as the 
compulsory companion of a positive sweat test. 
 
 
  
 
 
     
 
INTRODUCTION 
 
 
Cystic Fibrosis (CF) is in clinical practice erroneously often 
regarded as an exclusively pulmonary disease because much of 
the associated morbidity and mortality are related to pulmonary 
complications.1,2 This attitude not only reflects little clinical 
experience with the disease but reinforces the growing nasty 
habit not to include systematically a (pediatric) 
gastroenterologist in a CF team. Looking back on the original 
discovery of CF shows that it all started from the pancreas.      
In 1938 an American pathologist described her findings in the 
pancreas of young children, dead from extreme under nutrition 
caused by chronic malabsorption.3 Under her microscope the 
pancreas was full of small cysts filled with sticky mucus, 
surrounded by fibrous scar tissue. The new entity was therefore 
called “cystic fibrosis of the pancreas”. The pathology image 
perfectly explains these children’s past clinical history.4 
Normal pancreatic acini produce juice with digestive enzymes 
that is pushed on towards the duodenum. In CF however the 
pancreatic duct is obstructed by the sticky mucus and the acini 
are blown up to cysts.  In an attempt to protect the surrounding 
tissue forms fibrotic scars. The enzymes for digestion of fat, 
protein and starch do not reach their site of action, the intestinal 
lumen, and as a result these nutrients are not absorbed and pass 
largely unchanged in the stools which become voluminous, pale, 
greasy and malodorous.  The child thus neither receives 
materials nor energy to develop and function. It fails to thrive, 
does not grow and has a typical malabsorption profile (skinny, 
thin limbs and massively blown belly).5 Their muscles are weak 
like their resistance and at the first serious infection, they 
succumb. This natural history illustrates that originally the 
disease was purely digestive and it was thought that the fatal 
character was the result of the extreme malnutrition. Only once 
these children survived the first months and years of nutritional 
ordeal it became obvious that they also developed a specific 
primary respiratory disease. 
On the other hand once the sweat test had been developed as a 
diagnostic tool, some children with a positive sweat test were 
found to show little digestive problems. Their stools, growth, 
weight gain was almost normal and pancreatic function was 
only somewhat decreased. In contrast to the first group who was 
called pancreatic insufficient (PI) these ones were termed 
pancreatic sufficient (PS).3,5 In the years after initial diagnosis of 
exocrine pancreatic sufficiency the pancreas function can 
decline and a PS patient can irreversibly become PI. In a 5 year 
follow up period of a cohort of 184 CF patients Walkowiak et 
al.6 reported a decline in pancreatic function in 8/35 PS patients 
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who  were eventually diagnosed as PI. A decline in pancreatic 
function is seen more frequently in infants than older patients.6-8 
PANCREATIC FUNCTION AND CLINICAL 
MANIFESTATIONS 
The difference in pancreatic function has tremendous 
consequences for treatment and prognosis. In order to obtain a 
normal growth and weight, nutrition for PI patients should 
always be much richer in energy and thus in fat.5,9,10 This can 
only be absorbed when large quantities of pancreatic enzymes 
are ingested with every meal.5,11 These nutritional commitments 
can put a high burden on patient and family because weight can 
become an obsession. Nightmares are populated by words like 
“calories, BMI, fat, weight, eat” while PS patients hardly know 
their meaning.12-14 PS patients are remarkably different: as 
problems start later, most are somewhat older at diagnosis.  
They spontaneously grow, take weight and develop rather well, 
have less and milder exacerbations, a better survival and quality 
of life.15 In the early nineties PS were found to survive about 20 
years longer than PI. Was this just a result of the absence of 
malassimilation? The answer came about 25 years ago at the 
time of the description of the genotypes.16 More than 1500 
different were discovered which could be divided into severe or 
mild on the basis of their correlation to clinical course, 
prognosis but also pancreatic function. In contrast to PS, severe 
were most common in PI. However, according to Bradley et 
al.17 other genes than the CFTR one may play a role in the BMI 
variation.  
Other clinical manifestations are also associated with the 
pancreatic function. Meconium ileus is an exclusivity of PI. 
Problems with the handling of blood sugar mainly result from 
strangulation of insulin producing tissue in the pancreas by 
fibrotic scars and thus CF related diabetes is rarely seen in PS18 
patients. This is important since untreated diabetes can cost 
several years of life. Liver disease is also mainly seen in PI 
patients.19 Early screening for this complication is thus less 
important in PS. 
In summary, the difference in pancreatic function has important 
consequences. PI patients are at risk for malabsorption causing 
under nutrition and multiple deficiencies. They  need lifelong. 
nutritional counseling also on the importance of pancreatic 
enzyme replacement therapy. Even than they are not free of 
abdominal problems and a good weight gain and growth cannot 
be taken for granted.  They are prone to develop diabetes and 
liver disease. 
Respiratory evolution also needs to be followed closer because 
exacerbations are more frequent and more severe. 
This package of dazzling complications leaves no doubt that it is 
essential to have information on the pancreatic function of every 
patient. That this is not self evident is illustrated by the fact that, 
according to a patient registry in the United States in 2005 only 
less than 15% of all CF patients ever had their pancreatic 
function investigated. As a result erroneous pancreas enzyme 
replacement therapy was very frequent: in a large group of 1200 
patients 2% of the PI did not receive it and were thus at risk for 
debilitating under nutrition while it was superfluously 
administered to 54% of the PS.20 The latter is not dangerous but 
besides a waste of money, a needless charge to patients. Better 
results can easily be obtained since no complicated study’s are 
needed just a yes-no answer to the question “is the patient 
pancreatic insufficient and thus in need of pancreatic enzyme 
replacement therapy?” 
In the classically diagnosed infants who come to the doctor 
because of early complains the history and clinical presentation 
can already give indications on the digestive capacity. The 
pancreatic damage in cystic fibrosis already starts early in 
pregnancy and thus PI patients can already show subtle feeding 
problems from shortly after birth: despite a veracious appetite 
they fail to gain weight and produce large volumes of pale, 
yellow orange, greasy mal odorous stools. Soon they develop 
the typical malabsorption profile with protuberant belly. Closely 
watching growth and weight is essential because in retrospect 
the difference between PI and PS can often be read from the 
curves.21 PI CF infants with this presentation obviously come to 
the consultation earlier and are mostly earlier diagnosed than the 
PS without any early complaint. This clinical story mostly forms 
the key to pancreatic enzyme replacement therapy. 
Misconceptions are however common. The decision for lifelong 
enzyme replacement is too important to be only based on 
clinical impressions.20 In every patient there is an absolute need 
to substantiate it by the objective evidence of a biochemical test. 
This is certainly true in the case of diagnosis by neonatal 
screening where clinical abnormalities are absent. 
The scientific gold standard for biochemical tests22 is the direct 
measurement of enzymes in aspirated duodenal juice after the 
pancreas has been stimulated by the intravenous injection of two 
hormones, secretin and cholecystokinin (CCK). Although this 
secretine-CCK test is scientifically the most reliable it is in 
practice little performed in this young age group because it is 
not well standardized for infants and requires intestinal 
intubation, a rather invasive procedure. It is thus mainly 
reserved for scientific research and preference is given to the 
less invasive indirect tests.23 These can be divided into 3 
categories: the first measures the amount of undigested nutrients 
in the stools. In clinical practice the most popular test is the 72 
hour faecal fat balance study. It calculates the fat absorption 
coefficient over 3 days from measuring the amount of fat in a 72 
hour stool collection and relating it to the fat ingested over that 
period. It can be very accurate but defects in the completeness 
of the stool collection, the correct reporting of the ingested fat 
which has to be very high, the wide range of reported results and 
the distasteful character of the material make It mainly used for 
scientific work.  
The tests of the second group measure compounds from special 
products split up by pancreatic enzymes, in blood, urine or 
exhaled breath. Especially the detection of C13 in exhaled air 
after ingestion of marked triglycerides gives an excellent result 
but its practical realization requires special, expensive 
equipment and collection of the material can be difficult in 
infants.  
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The third group of tests consists of direct measurements of 
pancreatic enzymes or derivatives in blood or stools.  Those 
specific for the pancreas and performable on stool samples are 
preferred. Several candidates are valid but faecal elastase 1 
stands out above all others.24  
It is a specifically human pancreatic protease discharged in the 
bowel if at least the pancreatic duct is open, which is not the 
case in PI CF people. It is not degraded during its passage 
through the intestine and is even somewhat concentrated in the 
colon. During diarrhea dilution can thus make the result 
abnormally low. It is stable for several days at room temperature 
and can thus easily be transported to a central laboratory for 
examination. As the test distinguishes human elastase from 
porcine in the pancreatic enzyme preparation, it can be 
performed when the replacement therapy has already been 
started. The distinction between PI and PS is mostly easy 
because the concentrations in the first are mostly far below 
50µg/g stools while in the PS they are in THE lower range of 
normal’s, above 200 µg/g stools. In young PS CF children it is 
appropriate to repeat it whenever new symptoms cast doubt or 
systematically every year until the age of about 5 years because 
it can change in that group.6 This test is at this moment 
undoubtedly the most easy and most reliable for clinical use, 
with an excellent correlation to direct and other indirect tests.25 
It should therefore be used in clinical practice as the compulsory 
companion of a positive sweat test in order to know soon after 
diagnosis whether therapy should include nutritional counseling 
and pancreatic enzyme replacement. Only in that way can a 
diagnosis be regarded as fully conclusive.    
REFERENCES 
1. Raia V, Fuiano L, Staiano A. Editorial. The ESPGHAN 
Cystic Fibrosis Working Group: defining DIOS and 
constipation in cystic fibrosis with a multicenter study on 
the incidence, characteristics, and treatment of DIOS. J 
Pediatr Gastroenterol Nutr. 2010; 50(1): 8. 
2. Ooi CY, Durie PR. Cystic fibrosis from the 
gastroenterologist's perspective. Nat Rev Gastroenterol 
Hepatol. 2016. 
3. Andersen DH. Cystic fibrosis of the pancreas and its 
relation to celiac disease: A clinical and pathologic study. 
Am J Dis Child. 1938; 56(2). 
4. Culhane S, George C, Pearo B, Spoede E. Malnutrition in 
cystic fibrosis: a review. Nutr Clin Pract. 2013; 28(6): 
676-83. 
5. Sinaasappel M, Stern M, Littlewood J, Wolfe S, 
Steinkamp G, Heijerman HG, et al. Nutrition in patients 
with cystic fibrosis: a European Consensus. J Cyst Fibros. 
2002; 1(2): 51-75. 
6. Walkowiak J, Nousia-Arvanitakis S, Agguridaki Cet al. 
Longitudinal follow-up of exocrine pancreatic function in 
pancreatic sufficient cystic fibrosis patients using the fecal 
elastase-1 test. J Pediatr Gastroenterol Nutr. 2003; 36(4): 
474-8. 
7. Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, 
Hammond KB, Hambidge KM, et al. Pancreatic 
insufficiency, growth, and nutrition in infants identified by 
newborn screening as having cystic fibrosis. J Pediatr. 
1992; 120(4 Pt 1): 533-40. 
8. O'Sullivan BP, Baker D, Leung KG, Reed G, Baker SS, 
Borowitz D. Evolution of pancreatic function during the 
first year in infants with cystic fibrosis. J Pediatr. 2013; 
162(4): 808-12 e1. 
9. Matel JL. Nutritional management of cystic fibrosis. JPEN 
J Parenter Enteral Nutr. 2012; 36(Suppl I): 60S-7S. 
10. Woestenenk JW, Castelijns SJ, van der Ent CK, Houwen 
RH. Dietary intake in children and adolescents with cystic 
fibrosis. Clin Nutr. 2014; 33(3): 528-32. 
11. Somaraju UR, Solis-Moya A. Pancreatic enzyme 
replacement therapy for people with cystic fibrosis 
(Review). Paediatr Respir Rev. 2015; 16(2): 108-9. 
12. Filigno SS, Brannon EE, Chamberlin LA, Sullivan SM, 
Barnett KA, Powers SW. Qualitative analysis of parent 
experiences with achieving cystic fibrosis nutrition 
recommendations. J Cyst Fibros. 2012; 11(2): 125-30. 
13. Mitchell MJ, Powers SW, Byars KC, Dickstein S, Stark 
LJ. Family functioning in young children with cystic 
fibrosis: observations of interactions at mealtime. J Dev 
Behav Pediatr. 2004; 25(5): 335-46. 
14. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, 
Quinton H, Clinical Practice Guidelines on G, et al. 
Evidence-based practice recommendations for nutrition-
related management of children and adults with cystic 
fibrosis and pancreatic insufficiency: results of a 
systematic review. J Am Diet Assoc. 2008; 108(5): 832-9. 
15. Gilljam M, Ellis L, Corey M, Zielenski J, Durie P, Tullis 
DE. Clinical manifestations of cystic fibrosis among 
patients with diagnosis in adulthood. Chest. 2004; 126(4): 
1215-24. 
16. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel 
R, Grzelczak Z, et al. Identification of the cystic fibrosis 
gene: cloning and characterization of complementary 
DNA. Science. 1989; 245(4922): 1066-73. 
17. Bradley GM, Blackman SM, Watson CP, Doshi VK, 
Cutting GR. Genetic modifiers of nutritional status in 
cystic fibrosis. Am J Clin Nutr. 2012; 96(6): 1299-308. 
18. Moran A, Dunitz J, Nathan B, et al. Cystic fibrosis-related 
diabetes: current trends in prevalence, incidence, and 
mortality. Diabetes Care 2009; 32: 1626-1631. 
19. Ledder O, Haller W, Couper RT, et al. Cystic fibrosis: An 
update for clinicians. Part 2: Hepatobiliary and pancreatic 
manifestations. J Gastroenterol Hepatol 2014; 29: 1954-
1962. 
 
 
                          Robberecht et al. Int J Gastroenterol  Hepatol Transpl Nutr  2016;1(i): 7-10. 
 
 
10 
20. Borowitz D. Update on the evaluation of pancreatic 
exocrine status in cystic fibrosis. Curr Opin Pulm Med 
2005; 11: 524-7. 
21. Stephenson AL, Mannik LA, Walsh S, et al. Longitudinal 
trends in nutritional status and the relation between lung 
function and BMI in cystic fibrosis: a population-based 
cohort study. Am J Clin Nutr 2013; 97: 872-877. 
22. Leus J, Van Biervliet S, Robberecht E. Detection and 
followup of exocrine pancreatic insufficiency in cystic 
fibrosis: a review. Eur J Pediatr  2000; 159: 563–8. 
23. Walkowiak J, Nousia-Arvanitakis S, Henker J, et al. 
Indirect pancreatic function tests in children. J Pediatr 
Gastroenterol Nutr 2005; 40: 107-114. 
24. Daftary A,ActonJ,HoibyJ Fecal elastase-1.Utility in 
pancreatic function in cystic fibrosis J Cyst Fibrosis 2006, 
5(2); 71-76.      
25. Tardelli ACS, Camargos S, Paulo AM et al. Comparison 
of Diagnostic Methods for Pancreatic Insufficiency in 
Infants With Cystic Fibrosis J Pediatr Gastroent Nutr, 
2013, 56(2): 178-181 
 
 
Address reprint requests to: Eddy Robberecht, Belgradostr.56, 
B9000 Gent, Belgium. Tel: +32 -92230040; Email: 
eddy.robberecht@ugent.be 
 
 
 
